Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

NCT02194933 ↗

Phase 3 Completed 38 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.

Timeline

Start: 2015-02
Primary completion: 2016-04
Completion: 2016-04

Outcome

Mixed primary results

paper no statistically significant change in right VLPFC BOLD activation during the go/no-go task PMID 32450497 ↗

paper showed a significant decrease in right VLPFC BOLD activation during the stop-signal task PMID 32450497 ↗

Publications

van Erp TG, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG. Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study. Psychiatry Res Neuroimaging. 2020 Jul 30;301:111085. doi: 10.1016/j.pscychresns.2020.111085. Epub 2020 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brexpiprazole	Small molecule	2 mg	Oral
Subject	Brexpiprazole	Small molecule	4 mg	Oral